Telix announced it will acquire ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis, broadening its radiopharmaceutical and isotope capabilities. The deal could accelerate Telix's pipeline and strengthen its competitive position in nuclear medicine, but execution risk, financing considerations, and integration timelines may affect near-term cash flow and share valuation.
Telix Therapeutics is targeting a crucial FDA PDUFA date for TLX101-Px on September 11, addressing a significant medical need in brain cancer imaging. Analysts project that successful approval could lead to substantial revenue growth, boosting investor confidence and potentially increasing TLPPF's stock value.
Telix Pharmaceuticals has shown robust growth, particularly in its Precision Medicine unit, as reflected in a 5% increase in U.S. dose volumes. Analysts are optimistic, with Wedbush reiterating an Outperform rating and a $22 price target, likely driving interest in the stock.
Telix Pharmaceuticals reported aligned FY 2025 revenue of $804 million, with a strong fourth quarter performance. The U.S. launch of Gozellix supported this growth, and analysts remain optimistic despite the stock's significant decline over the past year. The stock's mixed momentum indicators suggest potential volatility ahead.
Telix's Q3 revenue reached $206 million, up 53% YoY. PSMA imaging revenue rose 17% to $155 million. Gozellix receives full CMS reimbursement effective October 1. Fiscal year 2025 sales guidance increased to $800M-$820M. Stock price increased 3.60% to $9.88.
Telix Pharmaceuticals received a Complete Response Letter from the FDA regarding TLX250-CDx. The CRL highlights deficiencies in the Chemistry, Manufacturing, and Controls package. Remediation is required for third-party manufacturing before resubmission to the FDA. Zircaix's approval is crucial as it would be the first PET scan drug for kidney cancer. Current stock price is down 13.18% following the news.
